AbCellera Biologics Inc. (ABCL) stock analysis
ABCL · AbCellera Biologics Inc.
Latest recorded price: USD 11.12
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth -46.3%, free cash flow margin -231.7%, ROIC -84.7%. The model flags 2 risk signals for this company (1 high severity).
Similar companies in Healthcare
- Absci Corporation - Common Stock (ABSI)
- Acadia Pharmaceuticals Inc. (ACAD)
- ADMA Biologics, Inc. (ADMA)
- Agios Pharmaceuticals, Inc. (AGIO)
- Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)
- AnaptysBio, Inc. - Common Stock (ANAB)
- Arrowhead Pharmaceuticals, Inc. - Common Stock (ARWR)
- Aurinia Pharmaceuticals Inc - Common Shares (AUPH)